2117 studies found for:    "Carcinoid tumor"
Show Display Options
Rank Status Study
1 Suspended Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Regional Digestive System Neuroendocrine Tumor G1
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
2 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
3 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis
4 Active, not recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
5 Terminated Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
6 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin
7 Unknown  Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention: Drug: RAD001 (everolimus, Afinitor®)
8 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
9 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
10 Active, not recruiting A Study of Axitinib in Advanced Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Axitinib
11 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
12 Not yet recruiting A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Ramucirumab;   Drug: Somatostatin Analog
13 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
14 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
15 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
16 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
17 Withdrawn Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Condition: Malignant Carcinoid Tumor
Intervention: Drug: 90Y-SMT487
18 Completed Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Lung Cancer
Interventions: Biological: recombinant interferon alfa;   Drug: fluorouracil
19 Completed
Has Results
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors
Intervention: Drug: Pasireotide (SOM230)
20 Completed
Has Results
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years